alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 890
Editorial Note: Nomenclature changes to part 890 appear at 73 FR 35341, June 23, 2008.

§ 890.5160 Air-fluidized bed. ( a ) *Identification.* An air-fluidized bed is a device employing the circulation of filtered air through ceramic spherules (small, round ceramic objects) that is intended for medical purposes to treat or prevent bedsores, to treat severe or extensive burns, or to aid circulation.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 890.9.
[48 FR 53047, Nov. 23, 1983, as amended at 63 FR 59231, Nov. 3, 1998]
§ 876.4330 Endoscopic pancreatic debridement device. ( a ) *Identification.* An endoscopic pancreatic debridement device is inserted via an endoscope and placed through a cystogastrostomy fistula into the pancreatic cavity. It is intended for removal of necrotic tissue from a walled off pancreatic necrosis (WOPN) cavity.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including evaluation of debridement of walled off pancreatic necrosis and all adverse events.
( 2 ) The patient-contacting components of the device must be demonstrated to be biocompatible.
( 3 ) Performance data must demonstrate the sterility of the patient-contacting components of the device.
( 4 ) The patient-contacting components of the device must be demonstrated to be non-pyrogenic.
( 5 ) Performance testing must support the shelf life of device components provided sterile by demonstrating continued sterility, package integrity, and device functionality over the labeled shelf life.
( 6 ) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: ( i ) Testing of rotational speeds and vacuum pressure;
( ii ) Functional testing including testing with all device components and the ability to torque the device; and
( iii ) Functional testing in a relevant tissue model to demonstrate the ability to resect and remove tissue.
( 7 ) Performance data must demonstrate the electromagnetic compatibility (EMC) and electrical safety of the device.
( 8 ) Software verification, validation, and hazard analysis must be performed.
( 9 ) Training must be provided so that upon completion of the training program, the user can resect and remove tissue of interest while preserving non-target tissue.
( 10 ) Labeling must include the following: ( i ) A summary of the clinical performance testing conducted with the device;
( ii ) Instructions for use, including the creation of a conduit for passage of endoscope and device into a walled off pancreatic necrotic cavity;
( iii ) Unless clinical performance data demonstrates that it can be removed or modified, a boxed warning stating that the device should not be used in patients with known or suspected pancreatic cancer;
( iv ) The recommended training for safe use of the device; and
( v ) A shelf life for any sterile components.
[89 FR 72986, Sept. 9, 2024]
#### § 895.20 General.

The Commissioner may initiate a proceeding to make a device a banned device whenever the Commissioner finds, on the basis of all available data and information, that the device presents substantial deception or an unreasonable and substantial risk of illness or injury that the Commissioner determines cannot be, or has not been, corrected or eliminated by labeling or by a change in labeling, or by a change in advertising if the device is a restricted device.

[44 FR 29221, May 18, 1979, as amended at 57 FR 58405, Dec. 10, 1992]
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 03-6866
UNITED STATES OF AMERICA, Plaintiff - Appellee, versus JOHN ANTHONY FRILANDO, a/k/a Chino Frilando, Defendant - Appellant. Appeal from the United States District Court for the District of South Carolina, at Florence. C. Weston Houck, Senior District Judge. (CR-97-84, CA-99-2842-4) Submitted: October 23, 2003 Decided: October 30, 2003 Before WILLIAMS, MOTZ, and SHEDD, Circuit Judges. Dismissed by unpublished per curiam opinion. John Anthony Frilando, Appellant Pro Se. Alfred William Walker Bethea, Assistant United States Attorney, Florence, South Carolina, for Appellee. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM: John Anthony Frilando seeks to appeal the district court’s order denying relief on his 28 U.S.C. § 2255 (2000) motion. Frilando cannot appeal this order unless a circuit judge or justice issues a certificate of appealability, and a certificate of appealability will not issue absent a “substantial showing of the denial of a constitutional right.” 28 U.S.C. § 2253(c)(2) (2000). A habeas appellant meets this standard by demonstrating that reasonable jurists would find that his constitutional claims are debatable and that any dispositive procedural rulings by the district court are also debatable or wrong. See Miller-El v. Cockrell , 537 U.S. 322, , 123 S. Ct. 1029, 1039 (2003); Slack v. McDaniel , 529 U.S. 473, 484 (2000); Rose v. Lee , 252 F.3d 676, 683 (4th Cir. 2001). We have independently reviewed the record and conclude Frilando has not made the requisite showing. Accordingly, we deny a certificate of appealability and dismiss the appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

DISMISSED
<TABLE> <S> <C>

<ARTICLE> 5

<S>                                       <C>
<PERIOD-TYPE>                             6-MOS
<FISCAL-YEAR-END>                                  DEC-31-1999
<PERIOD-START>                                     JAN-01-1999
<PERIOD-END>                                       JUN-30-1999
<CASH>                                              29,017,309
<SECURITIES>                                                 0
<RECEIVABLES>                                        1,114,507
<ALLOWANCES>                                           170,493
<INVENTORY>                                          2,657,437
<CURRENT-ASSETS>                                    33,365,381
<PP&E>                                              11,215,923
<DEPRECIATION>                                       5,813,062
<TOTAL-ASSETS>                                      42,024,709
<CURRENT-LIABILITIES>                                1,671,152
<BONDS>                                                      0
<PREFERRED-MANDATORY>                                        0
<PREFERRED>                                                  0
<COMMON>                                                40,097
<OTHER-SE>                                          20,115,460
<TOTAL-LIABILITY-AND-EQUITY>                        42,024,709
<SALES>                                              3,996,285
<TOTAL-REVENUES>                                     3,996,285
<CGS>                                                4,928,564
<TOTAL-COSTS>                                        4,928,564
<OTHER-EXPENSES>                                    12,951,222
<LOSS-PROVISION>                                             0
<INTEREST-EXPENSE>                                   1,317,927
<INCOME-PRETAX>                                     14,600,885
<INCOME-TAX>                                           114,060
<INCOME-CONTINUING>                                 14,486,825
<DISCONTINUED>                                               0
<EXTRAORDINARY>                                              0
<CHANGES>                                                    0
<NET-INCOME>                                        14,486,825
<EPS-BASIC>                                               3.64
<EPS-DILUTED>                                             2.39



</TABLE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Federal Reserve System

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the office of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than March 22, 2010.

**A. Federal Reserve Bank of Philadelphia**                     (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105-1521:                          ( print page 10485)    

*1. Patriot Financial Partners, GP, L.P.; Patriot Financial Partners, L.P.; Patriot Financial Partners Parallel, L.P.; Patriot Financial Partners, GP, LLC; Patriot Financial Managers, L.P.; Ira M. Lubert; W. Kirk Wycoff; and James J. Lynch*, all of Philadelphia, Pennsylvania; to acquire voting shares of Central Valley Community Bancorp, and thereby indirectly acquire voting shares of Central Valley Community Bank, both of Fresno, California.                

**B. Federal Reserve Bank of Kansas City**                     (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001:                

*1. Olen Ray Hibbard and William Michael Thompson*, both of Edmond, Oklahoma; as trustees of the Citizens Bancshares, Inc. Employee Stock Ownership Trust, Edmond, Oklahoma, to retain voting shares of Citizens Bancshares, Inc., and thereby indirectly retain voting shares of Citizens Bank of Edmond, both in Edmond, Oklahoma.                

Board of Governors of the Federal Reserve System, March 2, 2010.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 2010-4740 Filed 3-5-10; 8:45 am]

BILLING CODE 6210-01-S
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7599 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7599

     To amend title XVIII of the Social Security Act to expand the 
  eligibility for designation as a rural emergency hospital under the 
                           Medicare program.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 8, 2024

 Mr. LaTurner introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
     To amend title XVIII of the Social Security Act to expand the 
  eligibility for designation as a rural emergency hospital under the 
                           Medicare program.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Rural Emergency Hospital Adjustment 
Act''.

SEC. 2. EXPANDING THE ELIGIBILITY FOR DESIGNATION AS A MEDICARE RURAL 
              EMERGENCY HOSPITAL.

    Section 1861(kkk)(3) of the Social Security Act (42 U.S.C. 
1395x(kkk)(3)) is amended, in the matter preceding subparagraph (A), by 
striking ``as of'' and inserting ``at any point during the period 
beginning on January 1, 2015, and ending on''.
                                 <all>
```
| (logo) WELLS FARGO | **Commercial  Mortgage Servicing**D1050-084, 8th Floor  401 South Tryon Street  Charlotte, NC 28202  1-800-326-1334 |
|--------------------|---------------------------------------------------------------------------------------------------------------------|

 

 

**ANNUAL STATEMENT OF COMPLIANCE**

 

Reference is hereby made to that certain Pooling andServicing Agreement dated as of August 1, 2015, by and among Morgan StanleyCapital I Inc., as Depositor, Wells Fargo Bank, National Association, as MasterServicer, Midland Loan Services, A Division of PNC Bank, National Association,as Special Servicer, Park Bridge Lender Services LLC, as Trust Advisor,Wilmington Trust, National Association, as Trustee, and Wells Fargo Bank,National Association, as Certificate Administrator, Certificate Registrar,Authenticating Agent and Custodian with respect to Commercial MortgagePass-Through Certificates Series 2015-C24 (the "Agreement").Capitalized terms used herein not otherwise defined shall have the meaningsassigned in the Agreement. 

 

Pursuant to Section 13.9 of the Agreement, I, Daniel Bober,Executive Vice President of Commercial Mortgage Services do hereby certifythat:

 

1.      A review of the activities of the Master Servicer during the period fromJanuary 1, 2017 through December 31, 2017 (the “Reporting Period”), and of itsperformance per the Agreement during such period has been made under mysupervision, and 

 

2.     To the best of my knowledge, based on such review, the Master Servicer, hasfulfilled all of its obligations under the Agreement in all material respectsthroughout the Reporting Period. 

 

IN WITNESS WHEREOF, the undersigned has executed thisCertificate as of the 28th day of February 2018. 

 

 

/s/Daniel Bober

Daniel Bober

Executive Vice President

Wells Fargo Bank

 

 

| Wells Fargo Bank, N.A. | (logo) Together we’ll go  far |
|------------------------|-------------------------------------|
§ 884.4250 Expandable cervical dilator. ( a ) *Identification.* An expandable cervical dilator is an instrument with two handles and two opposing blades used manually to dilate (stretch open) the cervical os.
( b ) *Classification.* Class III (premarket approval).
( c ) *Date PMA or notice of completion of a PDP is required.* A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any expandable cervical dilator that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to an expandable cervical dilator that was in commercial distribution before May 28, 1976. Any other expandable cervical dilator shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
[45 FR 12684, Feb. 26, 1980, as amended at 52 FR 17741, May 11, 1987; 61 FR 50708, Sept. 27, 1996]
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1415 Ophthalmic trial lens frame. ( a ) *Identification.* An opthalmic trial lens frame is a mechanical device intended to hold trial lenses for vision testing.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[52 FR 33355, Sept. 2, 1987, as amended at 53 FR 35604, Sept. 14, 1988; 66 FR 38811, July 25, 2001]
§ 820.181 Device master record. Each manufacturer shall maintain device master records (DMR's). Each manufacturer shall ensure that each DMR is prepared and approved in accordance with § 820.40. The DMR for each type of device shall include, or refer to the location of, the following information: ( a ) Device specifications including appropriate drawings, composition, formulation, component specifications, and software specifications;
( b ) Production process specifications including the appropriate equipment specifications, production methods, production procedures, and production environment specifications;
( c ) Quality assurance procedures and specifications including acceptance criteria and the quality assurance equipment to be used;
( d ) Packaging and labeling specifications, including methods and processes used; and
( e ) Installation, maintenance, and servicing procedures and methods.
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.1850 Monitoring spirometer. ( a ) *Identification.* A monitoring spirometer is a device used to measure continuously a patient's tidal volume (volume of gas inhaled by the patient during each respiration cycle) or minute volume (the tidal volume multiplied by the rate of respiration for 1 minute) for the evaluation of the patient's ventilatory status.
( b ) *Classification.* Class II (performance standards).
#### § 82.1104 D&C Blue No. 4.

The color additive D&C Blue No. 4 shall conform in identity and specifications to the requirements of § 74.1104(a)(1) and (b) of this chapter. D&C Blue No. 4 is restricted to use in externally applied drugs and cosmetics.
I 

118TH CONGRESS 

2D SESSION H. R. 7959 

To amend the Immigration and Nationality Act with respect to inadmissibility 

and deportability related to squatting. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 11, 2024 

Mr. MEUSER (for himself, Mr. DUNCAN, Mr. RESCHENTHALER, Ms. 

MALLIOTAKIS, Mrs. MILLER-MEEKS, and Mr. CRENSHAW) introduced the 

following bill; which was referred to the Committee on the Judiciary 

A BILL 

To amend the Immigration and Nationality Act with respect 

to inadmissibility and deportability related to squatting. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Safeguarding Homes 

5 from Illegal Entry, Living, and Dwelling Act’’ or the 

6 ‘‘SHIELD Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7959 IH

1 SEC. 2. INADMISSIBILITY AND DEPORTABILITY RELATED 

2 TO SQUATTING. 

3 (a) INADMISSIBILITY.—Section 212(a)(2) of the Im4 migration and Nationality Act (8 U.S.C. 1182(a)(2)) is 

5 amended by adding at the end the following: 

6 ‘‘(J) TRESPASS.—Any alien who has been 

7 convicted of, who admits having committed, or 

8 who admits committing acts which constitute 

9 the essential elements of an offense for tres10 pass, as those terms are defined under the law 

11 of the jurisdiction where the conviction, offense, 

12 or acts constituting the essential elements of 

13 the offense occurred, without regard to whether 

14 the conviction or offense is classified as a mis15 demeanor or felony under Federal, State, tribal, 

16 or local law, is inadmissible.’’. 

17 (b) DEPORTABILITY.—Section 237(a)(2) of the Im18 migration and Nationality Act (8 U.S.C. 1227(a)(2)) is 

19 amended by adding at the end the following: 

20 ‘‘(G) TRESPASS.—Any alien who has been 

21 convicted of, who admits having committed, or 

22 who admits committing acts which constitute 

23 the essential elements of an offense for tres24 pass, as those terms are defined under the law 

25 of the jurisdiction where the conviction, offense, 

26 or acts constituting the essential elements of 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•HR 7959 IH

1 the offense occurred, without regard to whether 

2 the conviction or offense is classified as a mis3 demeanor or felony under Federal, State, tribal, 

4 or local law, is inadmissible.’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
§ 1.1001-5 European Monetary Union (conversion to the euro). ( a ) *Conversion of currencies.* For purposes of § 1.1001-1(a), the conversion to the euro of legacy currencies (as defined in § 1.985-8(a)(1)) is not the exchange of property for other property differing materially in kind or extent.
( b ) *Effect of currency conversion on other rights and obligations.* For purposes of § 1.1001-1(a), if, solely as the result of the conversion of legacy currencies to the euro, rights or obligations denominated in a legacy currency become rights or obligations denominated in the euro, that event is not the exchange of property for other property differing materially in kind or extent. Thus, for example, when a debt instrument that requires payments of amounts denominated in a legacy currency becomes a debt instrument requiring payments of euros, that alteration is not a modification within the meaning of § 1.1001-3(c).
( c ) *Effective date.* This section applies to tax years ending after July 29, 1998.
[T.D. 8927, 66 FR 2218, Jan. 11, 2001]
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.4500 Ear, nose, and throat microsurgical carbon dioxide laser. ( a ) *Identification.* An ear, nose, and throat microsurgical carbon dioxide laser is a device intended for the surgical excision of tissue from the ear, nose, and throat area. The device is used, for example, in microsurgical procedures to excise lesions and tumors of the vocal cords and adjacent areas.
( b ) *Classification.* Class II.